RGD Reference Report - Myosin7a deficiency results in reduced retinal activity which is improved by gene therapy. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Myosin7a deficiency results in reduced retinal activity which is improved by gene therapy.

Authors: Colella, P  Sommella, A  Marrocco, E  Di Vicino, U  Polishchuk, E  Garrido, MG  Seeliger, MW  Polishchuk, R  Auricchio, A 
Citation: Colella P, etal., PLoS One. 2013 Aug 26;8(8):e72027. doi: 10.1371/journal.pone.0072027. eCollection 2013.
RGD ID: 8694151
Pubmed: PMID:23991031   (View Abstract at PubMed)
PMCID: PMC3753344   (View Article at PubMed Central)
DOI: DOI:10.1371/journal.pone.0072027   (Journal Full-text)

Mutations in MYO7A cause autosomal recessive Usher syndrome type IB (USH1B), one of the most frequent conditions that combine severe congenital hearing impairment and retinitis pigmentosa. A promising therapeutic strategy for retinitis pigmentosa is gene therapy, however its pre-clinical development is limited by the mild retinal phenotype of the shaker1 (sh1(-/-)) murine model of USH1B which lacks both retinal functional abnormalities and degeneration. Here we report a significant, early-onset delay of sh1(-/-) photoreceptor ability to recover from light desensitization as well as a progressive reduction of both b-wave electroretinogram amplitude and light sensitivity, in the absence of significant loss of photoreceptors up to 12 months of age. We additionally show that subretinal delivery to the sh1(-/-) retina of AAV vectors encoding the large MYO7A protein results in significant improvement of sh1(-/-) photoreceptor and retinal pigment epithelium ultrastructural anomalies which is associated with improvement of recovery from light desensitization. These findings provide new tools to evaluate the efficacy of experimental therapies for USH1B. In addition, although AAV vectors expressing large genes might have limited clinical applications due to their genome heterogeneity, our data show that AAV-mediated MYO7A gene transfer to the sh1(-/-) retina is effective.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Usher Syndrome Type 1B treatmentIDA 8694151 RGD 
Usher Syndrome Type 1B  ISOMyo7a (Mus musculus)8694151; 8694151 RGD 
Usher Syndrome Type 1B treatmentISOMYO7A (Homo sapiens)8694151; 8694151 RGD 
Usher Syndrome Type 1B  IMP 8694151 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Myo7a  (myosin VIIA)

Genes (Mus musculus)
Myo7a  (myosin VIIA)

Genes (Homo sapiens)
MYO7A  (myosin VIIA)


Additional Information